Ensign Peak Advisors’s Soleno Therapeutics SLNO Stock Holding History

Ensign Peak Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,351	Closed	-$112K	–	1750
2026 Q1	$112K	Hold	3,351	–	–	﹤0.01%	1536
2025 Q4	$155K	Sell	3,351 -205,162	-98%	-$11.2M	﹤0.01%	1425
2025 Q3	$14.1M	Buy	208,513 +89,267	+75%	+$6.62M	0.02%	381
2025 Q2	$9.99M	Buy	119,246 +38,183	+47%	+$2.86M	0.02%	472
2025 Q1	$5.79M	Buy	81,063 +71,862	+781%	+$3.5M	0.01%	597
2024 Q4	$414K	Buy	9,201 +4,500	+96%	+$233K	﹤0.01%	1646
2024 Q3	$237K	Hold	4,701	–	–	﹤0.01%	1684
2024 Q2	$192K	Hold	4,701	–	–	﹤0.01%	1696
2024 Q1	$201K	Buy	+4,701	New	+$213K	﹤0.01%	1707

Ensign Peak Advisors's SLNO Position: Q2 2026 in Review

Ensign Peak Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 3,351 shares — an estimated $112K sold.

Ensign Peak Advisors first reported a position in SLNO in Q1 2024 and held it in 9 quarters. The position peaked at $14.1M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Ensign Peak Advisors reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Ensign Peak Advisors sold 3,351 Soleno Therapeutics shares in Q2 2026, an estimated $112K.
Ensign Peak Advisors first reported a position in Soleno Therapeutics in Q1 2024 and held it in 9 quarters.
Ensign Peak Advisors's Soleno Therapeutics position peaked at $14.1M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.